文献速递头颈部肿瘤放疗

T1-T2期与T3-T4期鼻咽癌患者海马保护调强放射治疗的剂量学评价

Dosimetric Evaluation of Hippocampus Sparing Intensity Modulated Radiation Therapy in Patients With Stage T1-T2 and Stage T3-T4 Nasopharyngeal Carcinoma.
PubMed 文献 · Adv Radiat Oncol · 2024-09-27

该回顾性研究纳入58例鼻咽癌患者,比较T1-T2期与T3-T4期患者海马保护调强放射治疗(IMRT)计划所降低的海马剂量,并分析海马剂量与PTVnx70体积的相关性。海马保护计划较非保护计划显著降低海马剂量学和体积学参数(P<.05),但Dmin、D98%和V5除外;T1-T2组多项剂量差值中位数显著低于T3-T4组。作者认为海马保护IMRT在T3-T4期鼻咽癌患者中降低海马Dmedian、Dmean、D40%及V30-V50的作用可能更显著。

要点

  • 海马保护IMRT较非保护计划显著降低海马剂量学和体积学参数(P<.05),但Dmin、D98%和V5除外。
  • T1-T2组Dmedian、Dmean、D40%、V30、V40、V50的差值中位数均显著低于T3-T4组(P<.05)。
  • 海马剂量学与体积学参数均与PTVnx70体积正相关(P<.05)。

核心结论

  • 海马保护IMRT计划在T3-T4期鼻咽癌患者中降低海马Dmedian、Dmean、D40%及V30-V50的作用可能较T1-T2期患者更显著。
  • 鼻咽癌患者PTVnx70体积与海马全部剂量学和体积学参数正相关,也与海马保护IMRT计划对特定剂量参数的降低幅度正相关。

研究设计与样本

  • 回顾性评估58例鼻咽癌患者,为每例患者分别设计海马保护与海马非保护IMRT计划,按鼻咽癌协议设计。
  • 采用剂量体积直方图评估每例患者的IMRT计划。
  • 比较T1-T2期组与T3-T4期组中海马保护与非保护计划间海马参数差值(如Dmin[NS]-Dmin[S])。
  • 分析海马剂量与PTVnx70体积的相关性。

主要发现

  • 海马保护与非保护IMRT计划之间无显著性差异。
  • 与非保护计划相比,海马保护计划显著降低海马剂量学和体积学参数(P<.05),但Dmin、D98%和V5除外。
  • T1-T2组Dmedian[NS]-Dmedian[S]、Dmean[NS]-Dmean[S]、D40%[NS]-D40%[S]、V30[NS]-V30[S]、V40[NS]-V40[S]和V50[NS]-V50[S]的中位数均显著低于T3-T4组(P<.05)。
  • 在海马保护和非保护计划中,海马剂量学和体积学参数均与PTVnx70体积正相关(P<.05)。
  • PTVnx70体积与Dmedian[NS]-Dmedian[S]、Dmean[NS]-Dmean[S]、D40%[NS]-D40%[S]、V40[NS]-V40[S]和V50[NS]-V50[S]正相关(P<.05)。

关键数值与推荐

  • 海马保护计划较非保护计划显著降低海马剂量学和体积学参数(P<.05),但Dmin、D98%和V5除外。
  • T1-T2组Dmedian[NS]-Dmedian[S]、Dmean[NS]-Dmean[S]、D40%[NS]-D40%[S]、V30[NS]-V30[S]、V40[NS]-V40[S]和V50[NS]-V50[S]的中位数均显著低于T3-T4组(P<.05)。
  • PTVnx70体积与Dmedian[NS]-Dmedian[S]、Dmean[NS]-Dmean[S]、D40%[NS]-D40%[S]、V40[NS]-V40[S]和V50[NS]-V50[S]正相关(P<.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the hippocampus (HPC) dose reduced by HPC-sparing intensity modulated radiation therapy (IMRT) plans between nasopharyngeal carcinoma (NPC) patients of stages T1-T2 and T3-T4, and to investigate the correlation between the dose of the HPC and the volume of PTVnx70 (the planning target volume of the primary tumor in the nasopharynx that received 70 Gy). METHODS AND MATERIALS: Fifty-eight NPC patients were retrospectively evaluated. HPC-nonsparing IMRT or sparing IMRT for each patient was designed according to the protocol for NPC. Dose-volume histogram was used to evaluate the IMRT plans for each patient. The difference in values of HPC parameters (eg, Dmin[NS] - Dmin[S]) between HPC-sparing and nonsparing plans in the stage T1-T2 group and stage T3-T4 group were compared. The correlations between the dose of the HPC and the volume of PTVnx70 were analyzed. RESULTS: There was no significance between HPC-sparing and nonsparing IMRT plans. Compared with the HPC-nonsparing plans, the HPC-sparing plans significantly decreased both dosimetric and volumetric parameters for the HPC (P < .05), except for Dmin, D98%, and V5. The medians of Dmedian[NS] - Dmedian[S], Dmean[NS] - Dmean[S], D40%[NS] - D40%[S], V30[NS] - V30[S], V40[NS] - V40[S] and V50[NS] - V50[S] in the T1-T2 group were significantly lower than in the T3-T4 group (P < .05), respectively. Both dosimetric and volumetric parameters for the HPC were positively correlated with the volume of PTVnx70 in HPC-sparing and HPC-nonsparing plans (P < .05). The volume of PTVnx70 was positively correlated with Dmedian[NS] - Dmedian[S], Dmean[NS] - Dmean[S], D40%[NS] - D40%[S], V40[NS] - V40[S] and V50[NS] - V50[S] (P < .05). CONCLUSIONS: HPC-sparing IMRT plans may play a more significant role in decreasing Dmedian, Dmean, D40%, and V30-V50 of HPC in NPC patients with stages T3-T4 than those in stages T1-T2. PTVnx70 volume of NPC patients is positively correlated with all dosimetric and volumetric parameters of HPC and the reduction of specific dosage parameters by HPC-sparing IMRT plans.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou X, Wu K, Prasad N, et al. Dosimetric Evaluation of Hippocampus Sparing Intensity Modulated Radiation Therapy in Patients With Stage T1-T2 and Stage T3-T4 Nasopharyngeal Carcinoma. Adv Radiat Oncol. 2024. PMID: 39610798. doi:10.1016/j.adro.2024.101646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。